🏛️ Verified NIH Record • Updated 2025-08-22
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease (NCT06765668)
Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients
🟢 Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: Impax Laboratories, LLC
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
Who can join: Review the eligibility criteria below.
Location: Barrow Neurological Institute — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- Barrow Neurological Institute — Phoenix, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Parkinson's Research Centers of America - Orange County — Aliso Viejo, California
- Parkinson's Research Centers of America - Palo Alto — Palo Alto, California
- Visionary Investigators Network — Aventura, Florida
- Parkinsons Disease and Movement Disorders Center of Boca Raton — Boca Raton, Florida
- Univesity of Miami - Miller School of Medicine — Boca Raton, Florida
- University of Miami — Miami, Florida
- N1 Research LLC — Orlando, Florida
- USF Parkinson's Disease and Movement Disorders Center — Tampa, Florida
- Central DuPage Hospital - Movement Disorders Center — Winfield, Illinois
- University of Kansas Medical Center — Kansas City, Kansas
- Quest Research Institute — Farmington Hills, Michigan
- Cleveland Clinic Lou Ruvo Center for Brain Health — Las Vegas, Nevada
- Parkinson's Research Centers of America - Long Island — Commack, New York
- Atrium Health Wake Forest Baptist Adult Neurology - Janeway Tower — Winston-Salem, North Carolina
- NeuroScience Research Center, LLC — Canton, Ohio
- University of Cincinnati — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- The Movement Disorder Clinic of Oklahoma — Tulsa, Oklahoma
- Neurology Consultants of Dallas, PA — Dallas, Texas
- Texas Movement Disorder Specialists, PLLC — Georgetown, Texas
- Icahn School of Medicine at Mount Sinai — Houston, Texas
- The University of Texas Health Science Center at Houston- McGovern Medical School — Houston, Texas
- Inova Neurology — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (602) 406-4280
Email: MovementResearch@dignityhealth.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Parkinson Disease
- Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation — Tucson, Arizona
- Parkinson's Disease Progression Study — Aurora, Colorado
- To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications — Birmingham, Alabama
- Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower) — Seattle, Washington
- Automated Imaging Differentiation of Parkinsonism — Birmingham, Alabama
- Study in Parkinson Disease of Exercise — Birmingham, Alabama
Explore by condition: All Parkinson Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.